Press Releases
31.05.10
Mucosis receives financial support from the Dutch government for its FluGEM program
Dutch vaccine development company Mucosis B.V. announced today that it has received an innovation credit line of approximately € 3 million from Agentschap NL, an agency of the Dutch Ministry of Economic Affairs. Mucosis will use this loan towards the clinical development of its lead product FluGEM™, an influenza vaccine that can be administered by a simple spray in the nose. The loan will be redeemed only if the FluGEM™ clinical development program is concluded successfully.
read more >
27.04.10
Mucosis appoints Dr. Roberto Grimandi as chief medical officer
Dutch vaccine development company MUCOSIS B.V. announced today that Dr. Roberto Grimaldi, MD was appointed Chief Medical Officer at Mucosis. Dr. Grimaldi is an accomplished executive and consultant to the vaccine industry who brings over 25 years of experience. As an expert on vaccine development he will lead the Mucosis development programs into clinical trials in the near future.
read more >
22.09.09
Mucosis receives key US patent covering its Mimopath™ technology
Dutch biotechnology company MUCOSIS B.V. announced today that it has been granted a key patent by the United States Patent and Trademark Office for its Mimopath™ technology, a new invention in the field of vaccines. Patents for this proprietary technology have also been granted in the European Union and China.
read more >
28.01.09
MUCOSIS B.V. and PATH start development of pneumococcal vaccines
Dutch biotechnology company Mucosis B.V. and the global nonprofit organization PATH today announced a partnership to advance the development of pneumococcal vaccine candidates.
read more >
15.12.08
MUCOSIS B.V. and TNO announce flu vaccine research and development partnership.
Dutch biotechnology company Mucosis B.V. and the Netherlands Organization for Applied Scientific Research TNO today announced that they have entered into a collaboration agreement to further develop an intranasal influenza vaccine.
read more >
10.12.08
News article in “Het Financieele Dagblad”.
Geen product, geen winst, maar wel dromen van een multinational
(No product or profit yet, but having a dream of a multinational enterprise)
‘Dit is het hart van ons bedrijf.’ Bestuursvoorzitter Govert Schouten van het Groningse biotechbedrijf Mucosis staat in een laboratorium. Rechts warmhoudkasten, links koelkasten, op tafel staat een vreemd apparaat waar een aantal slangetjes uit komt. Uit een koelkast pakt hij een reageerbuisje met troebele vloeistof. Dat zijn behandelde melkzuurbacteriën, dé technologie die het bedrijfje groot moet maken.
read more >
06.11.08
Mucosis B.V. appoints Dr. Govert Schouten as CEO.
Dutch biotechnology company Mucosis B.V. today announced the appointment
of Dr. Govert Schouten to the position of Chief Executive Officer.
"We are very pleased to have a person with Dr. Schouten’s business and strategic
background join Mucosis," said Dr. Willem Hazenberg, chairman of the supervisory
board of Mucosis and partner at Mucosis’s lead investor BioGeneration Ventures B.V.
"His extensive experience in the vaccine industry will make an important contribution to Mucosis's ambitious growth strategy for the coming years”.
read more >
10.09.07
Mucosis raises € 3 million in first financinground
Groningen, 10 September 2007. Dutch-based vaccine development company Mucosis BV today announced the successful completion of a € 3 million first round of financing. A consortium consisting of BioGeneration Ventures (lead investor), MedSciences Capital, and NV NOM, Investment and Development Agency for the Northern Netherlands, participated in this equity investment.
read more >